Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773915 | 0.86 | NR4A2 (0.58) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL3773383 | 0.86 | NR4A2 (0.58) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL1734081 | 0.85 | NR4A2 (0.57) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL3777392 | 0.83 | NR4A2 (0.55) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL1732978 | 0.83 | NR4A2 (0.80) | NR4A2CYP2C9GRM5 | |
| SCHEMBL1733042 | 0.82 | NR4A2 (0.54) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL3369722 | 0.82 | RAB9A (0.68) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL1733793 | 0.79 | NR4A2 (0.62) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL1733358 | 0.78 | NR4A2 (0.58) | NR4A2CYP2C9NPC1RAB9AKDM4E | |
| SCHEMBL1733565 | 0.78 | NR4A2 (0.58) | NR4A2CYP2C9NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317673-A1 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | IDH2, GLS, IDH1 | NR4A2 1193/4885CYP2C9 1454/4885SORT1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.